Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
27.75
-0.37 (-1.32%)
Oct 29, 2024, 4:00 PM EDT - Market closed
Company Description
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases.
It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Dianthus Therapeutics, Inc.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 53 |
| CEO | Marino Garcia |
Contact Details
Address: 7 Times Square, 43rd Floor New York, New York 10036 United States | |
| Phone | 929 999 4055 |
| Website | dianthustx.com |
Stock Details
| Ticker Symbol | DNTH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001690585 |
| CUSIP Number | 252828108 |
| ISIN Number | US2528281080 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Marino Garcia M.B.A. | President, Chief Executive Officer, Secretary and Director |
| Ryan Savitz | Chief Financial Officer and Chief Business Officer and Treasurer |
| Simrat Randhawa M.B.A., M.D. | Chief Medical Officer |
| Edward G. Carr | Chief Accounting Officer |
| Judson Taylor | Head of Technical Operations |
| Dr. Jeffrey Stavenhagen Ph.D. | Chief Scientific Officer |
| Jennifer Davis Ruff | Vice President and Head of Investor Relations and Corporate Affairs. |
| Adam M. Veness Esq. | Senior Vice President, General Counsel and Secretary |
| Kristina Maximenko | Chief People Officer |
| Rashieda Gluck | Head of Clinical Development Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 24, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 21, 2024 | RW | Filing |
| Oct 11, 2024 | 424B5 | Filing |
| Oct 11, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 11, 2024 | 424B3 | Prospectus |
| Oct 9, 2024 | EFFECT | Notice of Effectiveness |
| Oct 9, 2024 | EFFECT | Notice of Effectiveness |
| Oct 1, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Oct 1, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Sep 16, 2024 | 424B3 | Prospectus |